Article Information
History
- May 31, 2020.
Article Versions
- You are currently viewing Version 1 of this article (May 31, 2020 - 22:48).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Emily F. Davis-Marcisak1,2,6,
- Allison A. Fitzgerald3,6,
- Michael D. Kessler2,
- Ludmila Danilova2,
- Elizabeth M. Jaffee2,
- Neeha Zaidi2,
- Louis M. Weiner3 and
- Elana J. Fertig2,4,5,*
- 1McKusick-Nathans Institute of the Department of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
- 2Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA
- 3Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
- 4Department of Applied Mathematics and Statistics, Johns Hopkins University Whiting School of Engineering, Baltimore, MD, USA
- 5Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- ↵*Corresponding author; email: ejfertig{at}jhmi.edu
↵6 These authors contributed equally to this work
Posted May 31, 2020.
A novel mechanism of natural killer cell response to anti-CTLA-4 therapy identified by integrative analysis of mouse and human tumors
